Expertise in
1
conditions

Dr. Melanie E. Royce

Internal Medicine
Unm Cancer Ctr, 1201 Camino De Salud Ne, 
Albuquerque, NM 
Expertise in
1
conditions
Unm Cancer Ctr, 1201 Camino De Salud Ne, 
Albuquerque, NM 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Melanie Royce is a primary care provider, practicing in Internal Medicine in Albuquerque, New Mexico. Dr. Royce is highly rated in 1 condition, according to our data. Her top areas of expertise are Breast Cancer, HER-2 Positive Breast Cancer, Breast Cancer in Men, and Lymphomatoid Papulosis.

Her clinical research consists of co-authoring 37 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Internal Medicine
Licenses
Internal Medicine in NM
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

Unm Cancer Ctr, 1201 Camino De Salud Ne, Albuquerque, NM 87131

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer With Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Exemestane, Letrozole, Systemic Chemotherapy
Study Phase: Phase 3
Expanded Breast Cancer Registry and Tissue Repository
Expanded Breast Cancer Registry and Tissue Repository
Enrollment Status: Completed
Publish Date: May 22, 2025
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
Enrollment Status: Completed
Publish Date: May 16, 2025
Intervention Type: Other, Drug
Study Drugs: Cisplatin, Veliparib
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Phase II Trial of Combination Immunotherapy With Nelipepimut-S + GM-CSF (NeuVax™) and Trastuzumab in High-risk HER2+ Breast Cancer Patients
Enrollment Status: Completed
Publish Date: December 12, 2023
Intervention Type: Biological, Drug
Study Drugs: NeuVax vaccine, Trastuzumab, GM-CSF
Study Phase: Phase 2
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations
Enrollment Status: Terminated
Publish Date: June 18, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 5 Less Clinical Trials

37 Total Publications

FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer.
FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 16, 2025
Similar Doctors
Expertise in
13
conditions
Dr. Edward Lewiecki
Internal Medicine
Expertise in
13
conditions
Dr. Edward Lewiecki
Internal Medicine

New Mexico Clinical Research And Osteoporosis Center, Inc

300 Oak St Ne, 
Albuquerque, NM 
 (0.9 miles away)
505-855-5525
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edward Lewiecki is a primary care provider, practicing in Internal Medicine in Albuquerque, New Mexico. Dr. Lewiecki is highly rated in 13 conditions, according to our data. His top areas of expertise are Osteoporosis, Postmenopausal Osteoporosis, Premature Ovarian Failure, and Hypogonadism Primary Partial Alopecia.

Expertise in
9
conditions
Dr. Abu B. Sheikh
Internal Medicine
Expertise in
9
conditions
Dr. Abu B. Sheikh
Internal Medicine

Unm Medical Group Inc

2211 Lomas Blvd Ne, 
Albuquerque, NM 
 (0.7 miles away)
505-272-2111
Experience:
9+ years
Languages Spoken:
English
See accepted insurances

Abu Sheikh is a primary care provider, practicing in Internal Medicine in Albuquerque, New Mexico. Dr. Sheikh has been practicing medicine for over 9 years is highly rated in 9 conditions, according to our data. His top areas of expertise are COVID-19, Sepsis, Diabetes Insipidus (DI), Thrombectomy, and Endoscopy.

Expertise in
7
conditions
Dr. Lance Rudolph
Internal Medicine
Expertise in
7
conditions
Dr. Lance Rudolph
Internal Medicine

New Mexico Clinical Research And Osteoporosis Center, Inc

300 Oak St Ne, 
Albuquerque, NM 
 (0.9 miles away)
505-855-5525
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lance Rudolph is a primary care provider, practicing in Internal Medicine in Albuquerque, New Mexico. Dr. Rudolph is highly rated in 7 conditions, according to our data. His top areas of expertise are Osteoporosis, Postmenopausal Osteoporosis, Hypogonadism Primary Partial Alopecia, and Premature Ovarian Failure.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Royce's expertise for a condition
ConditionClose
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile